Castle Biosciences (CSTL) Payables (2018 - 2026)

Castle Biosciences has reported Payables for 9 years, with the latest figure at $9.7 million in Q2 2026.

• Quarterly Payables fell 26.65% year-over-year to $9.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.7 million (down 26.65% YoY) and the FY2025 annual result came in at $18.7 million, up 171.13% from the prior year.
• Payables slipped to $9.7 million in Q2 2026 per CSTL's latest filing, from $15.0 million in the prior quarter.
• Over five years, Payables peaked at $18.7 million in Q4 2025 and troughed at $3.3 million in Q2 2022.
• A 5-year average of $9.0 million and a median of $8.9 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2024: Payables soared 200.57% in 2023, then plunged 32.79% in 2024.
• Over 5 years, Payables stood at $4.7 million in 2022, then surged by 117.04% to $10.3 million in 2023, then sank by 32.79% to $6.9 million in 2024, then soared by 171.13% to $18.7 million in 2025, then sank by 48.33% to $9.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $9.7 million, $15.0 million, and $18.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.